OSCOTEC Signs Global License Agreement for SYK Inhibitor Cebidoplenib - $25M Upfront and Up to $640M Milestones, Enhancing Shareholder Value
OSCOTEC has entered into a global exclusive license agreement with Agios Pharmaceuticals for its SYK inhibitor candidate, cebidoplenib (SKI-O-703). The company will receive an upfront payment of $25 million (approx. 37.5B KRW) and is eligible for up to $640 million (approx. 96.2B KRW) in development and commercial milestones, plus tiered royalties on net sales.
The upfront and milestones are non-refundable, and OSCOTEC has no penalty obligations if the agreement is terminated due to clinical or regulatory failures. However, revenue recognition depends on successful clinical development and regulatory approvals.
Revenue will be split 75% to OSCOTEC and 25% to its subsidiary, Genosco. The upfront payment is expected within 30 days of the effective date, and a follow-up disclosure will be made upon receipt.
This technology export deal validates the global potential of cebidoplenib, providing immediate cash inflow of $25M and long-term upside from milestones and royalties, positively impacting shareholder value.
[AI Summary]The license agreement with Agios represents a major milestone for OSCOTEC, securing $25M upfront and up to $640M in milestones, significantly improving cash flow and future revenue prospects. While clinical and regulatory risks remain, the deal substantially enhances the company's valuation and shareholder returns.
KOSDAQ Filing Information
Filing: Key Management Matters Related to Investment Decision (Conclusion of Technology Export Contract for SYK Inhibitor Candidate Sevidoplenib (SKIO703))